AHR and prostate carcinoma: Since, apparently, antagonism of the AhR is not the only mechanism of increase of NK activity by urolithin A, we have preliminarily studied the influence of urolithin A (also in the absence and in the presence of AhR agonist or antagonist) on the production of panel of inflammatory cytokines by PBMCs of patients with prostate cancer and healthy subjects (Figure 4).